

# **MJ Health Research Foundation**

## **Compensation Scheme for Commercial Applications of MJ Biobank Resources**

Reviewed and approved by MJ Foundation Ethics Committee on March 17, 2014

Article 1: The MJ Health Research Foundation administers the MJ Biobank (hereinafter, the “Biobank”) for the commercial development of applications based on the Biobank’s biological samples. The “Human Biobank Commercial Application Compensation Act” provides means for assessing appropriate compensation for use in the “Compensation Scheme for Commercial Applications of MJ Biobank Resources” (hereinafter, the “Compensation Scheme”).

Article 2: In the Compensation Scheme, “users” refers to natural or legal persons, research institutions or for-profit enterprises seeking to use biological specimens, data, or information from the Biobank.

Article 3: In the compensation scheme, “commercial use” refers to business-related revenue generated using the Biobank’s biological samples, data, or information. Profit sharing between the User and Biobank does not cover fees for the collection, storage and provision of biological samples, data, and information from the Biobank.\_

Article 4: The Biobank may charge fixed fees according to the nature and quantity of specimens or data required by the user. Such fees will be set according to industry standards. The user must provide a complete description of the proposed commercial application to serve as the basis for determination for a profit sharing agreement by the Biobank and the user. When the user is the Biobank itself, the fees will be determined by the Foundation’s Ethics Committee.

Article 5: Of the profit sharing assigned to the Foundation, not less than 50% will be

returned to the donor population or their representatives.

Article 6: Commercial applications based on Biobank resources and the corresponding benefits from the previous year will be regularly published on the Foundation's website before the end of each January.

Article 7: Conditions not covered by these regulations will be determined based on the "Human Biobank Commercial Application Compensation Act".

Article 8: These measures shall be promulgated and implemented following approval by the Foundation's Ethics Committee and Board of Directors, along with any future amendments.